AFT-28 Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)

Grants and Contracts Details

Description

HUMAN CLINICAL TRIAL - CONFIDENTIAL The study design is a randomized effectiveness study to evaluate the effectiveness of DOAC therapy compared to usual care with LMWH/warfarin. Participants who decline randomization will be offered the opportunity to participate in the preference cohort. This is a hybrid design that consists of both a randomized cohort and a preference cohort. Eligible patients who accept randomization will be enrolled in the study (the randomized cohort), and they will be randomly assigned to either the DOAC therapy group (Arm 1) or the usual care group (Arm 2). Those patients who decline randomization but choose treatment on one of the two study arms (Arm 1 or Arm 2) will be enrolled to the study (the preference cohort).
StatusFinished
Effective start/end date4/25/1710/10/22

Funding

  • Alliance Foundation Trials LLC: $23,250.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.